{"id": "article-25785_0", "title": "Neurofibromatosis -- Continuing Education Activity", "content": "Neurofibromatosis is a neurocutaneous disorder characterized by tumors in the nervous system and skin. The most common types of neurofibromatosis are types 1 and 2, both of which are autosomal dominant. Neurofibromatosis type 1, also known as von Recklinghausen disease, presents with neurofibromas, cafe-au-lait spots, freckling, and optic gliomas. Neurofibromatosis type 2 is characterized by bilateral vestibular schwannomas and meningiomas. Treatment for neurofibromatosis types 1 and 2 involves clinical monitoring and medical intervention when appropriate. This activity describes the pathophysiology, evaluation, and management of neurofibromatosis and highlights the role of the interprofessional team in caring for patients affected by this condition.", "contents": "Neurofibromatosis -- Continuing Education Activity. Neurofibromatosis is a neurocutaneous disorder characterized by tumors in the nervous system and skin. The most common types of neurofibromatosis are types 1 and 2, both of which are autosomal dominant. Neurofibromatosis type 1, also known as von Recklinghausen disease, presents with neurofibromas, cafe-au-lait spots, freckling, and optic gliomas. Neurofibromatosis type 2 is characterized by bilateral vestibular schwannomas and meningiomas. Treatment for neurofibromatosis types 1 and 2 involves clinical monitoring and medical intervention when appropriate. This activity describes the pathophysiology, evaluation, and management of neurofibromatosis and highlights the role of the interprofessional team in caring for patients affected by this condition."}
{"id": "article-25785_1", "title": "Neurofibromatosis -- Continuing Education Activity", "content": "Objectives: Identify the etiology of neurofibromatosis. Describe the presentation of a patient with neurofibromatosis. Summarize the treatment and management options available for neurofibromatosis. Explain interprofessional team strategies for improving care coordination and communication to advance the treatment of neurofibromatosis and improve outcomes. Access free multiple choice questions on this topic.", "contents": "Neurofibromatosis -- Continuing Education Activity. Objectives: Identify the etiology of neurofibromatosis. Describe the presentation of a patient with neurofibromatosis. Summarize the treatment and management options available for neurofibromatosis. Explain interprofessional team strategies for improving care coordination and communication to advance the treatment of neurofibromatosis and improve outcomes. Access free multiple choice questions on this topic."}
{"id": "article-25785_2", "title": "Neurofibromatosis -- Introduction", "content": "Neurofibromatosis is a neurocutaneous disorder characterized by tumors in the nervous system and skin. Neurofibromatosis types 1 and 2 are the most common and are distinct entities. Neurofibromatosis type 1, or von Recklinghausen disease, is an autosomal dominant disease.\u00a0Neurofibromatosis type 1\u00a0presents with neurofibromas, cafe-au-lait macules, freckling, and optic gliomas. It is a clinical diagnosis. Neurofibromatosis type 2 (NF2) is a disease characterized by bilateral vestibular schwannomas (VS) and meningiomas. It has an autosomal dominant inheritance pattern. Treatment for neurofibromatosis types 1\u00a0and 2 is clinical monitoring and medical intervention when appropriate. [1] [2] [3]", "contents": "Neurofibromatosis -- Introduction. Neurofibromatosis is a neurocutaneous disorder characterized by tumors in the nervous system and skin. Neurofibromatosis types 1 and 2 are the most common and are distinct entities. Neurofibromatosis type 1, or von Recklinghausen disease, is an autosomal dominant disease.\u00a0Neurofibromatosis type 1\u00a0presents with neurofibromas, cafe-au-lait macules, freckling, and optic gliomas. It is a clinical diagnosis. Neurofibromatosis type 2 (NF2) is a disease characterized by bilateral vestibular schwannomas (VS) and meningiomas. It has an autosomal dominant inheritance pattern. Treatment for neurofibromatosis types 1\u00a0and 2 is clinical monitoring and medical intervention when appropriate. [1] [2] [3]"}
{"id": "article-25785_3", "title": "Neurofibromatosis -- Etiology", "content": "Neurofibromatosis type 1\u00a0is caused by a loss of function mutation, either de novo or inherited, on the neurofibromin\u00a01 (NF1 )\u00a0gene. It is located on band 17q11.2 and codes for neurofibromin. Neurofibromin is a tumor suppressor that functions in the RAS/MAPK and mTOR pathways. Mosaicism can occur, resulting in the segmental, generalized, or gonadal NF1 gene. Segmental NF1 gene\u00a0has pigment changes, tumors, or both that are limited to one or more body segments. Generalized NF1 gene\u00a0appears similar to classic NF1 but does not have the NF1 gene mutation. Gonadal NF1 gene\u00a0occurs when the mutation only affects the ova or sperm.", "contents": "Neurofibromatosis -- Etiology. Neurofibromatosis type 1\u00a0is caused by a loss of function mutation, either de novo or inherited, on the neurofibromin\u00a01 (NF1 )\u00a0gene. It is located on band 17q11.2 and codes for neurofibromin. Neurofibromin is a tumor suppressor that functions in the RAS/MAPK and mTOR pathways. Mosaicism can occur, resulting in the segmental, generalized, or gonadal NF1 gene. Segmental NF1 gene\u00a0has pigment changes, tumors, or both that are limited to one or more body segments. Generalized NF1 gene\u00a0appears similar to classic NF1 but does not have the NF1 gene mutation. Gonadal NF1 gene\u00a0occurs when the mutation only affects the ova or sperm."}
{"id": "article-25785_4", "title": "Neurofibromatosis -- Etiology", "content": "NF2 gene\u00a0is caused by a loss of function mutation of the NF2 gene. It is located on band 22q12 and codes for merlin. Merlin is a cell membrane protein that is also a tumor suppressor that functions in the PI3kinase/Akt, Raf/MEK/ERK, and mTOR pathways. [4] [5]", "contents": "Neurofibromatosis -- Etiology. NF2 gene\u00a0is caused by a loss of function mutation of the NF2 gene. It is located on band 22q12 and codes for merlin. Merlin is a cell membrane protein that is also a tumor suppressor that functions in the PI3kinase/Akt, Raf/MEK/ERK, and mTOR pathways. [4] [5]"}
{"id": "article-25785_5", "title": "Neurofibromatosis -- Epidemiology", "content": "Neurofibromatosis\u00a0type 1\u00a0makes up about 96% of all neurofibromatosis cases. Prevalence is 1 in 3000 births. It occurs equally between gender and races. Fifty percent of patients have a spontaneous mutation, and the other half have an inherited mutation. There is a 100% penetrance with variable expressivity.\u00a0Neurofibromatosis\u00a0type 2\u00a0makes up about 3% of all cases and has a prevalence between 1 in 33,000 births and 1 in 87,410. There is no gender or race predilection.\u00a0Neurofibromatosis\u00a0type 2\u00a0has variable presentations amongst different families. A more severe clinical presentation is associated with a frameshift or a nonsense mutation that results in a truncated protein. [6]", "contents": "Neurofibromatosis -- Epidemiology. Neurofibromatosis\u00a0type 1\u00a0makes up about 96% of all neurofibromatosis cases. Prevalence is 1 in 3000 births. It occurs equally between gender and races. Fifty percent of patients have a spontaneous mutation, and the other half have an inherited mutation. There is a 100% penetrance with variable expressivity.\u00a0Neurofibromatosis\u00a0type 2\u00a0makes up about 3% of all cases and has a prevalence between 1 in 33,000 births and 1 in 87,410. There is no gender or race predilection.\u00a0Neurofibromatosis\u00a0type 2\u00a0has variable presentations amongst different families. A more severe clinical presentation is associated with a frameshift or a nonsense mutation that results in a truncated protein. [6]"}
{"id": "article-25785_6", "title": "Neurofibromatosis -- Histopathology", "content": "Neurofibromas are benign tumors with mixed cell types, including Schwann cells, perineural cells, and fibroblasts. The tumors also contain mast cells, axonal processes, and a collagenous extracellular matrix. Plexiform neurofibromas are similar to neurofibromas, but they arise from muscle nerve fascicles and can infiltrate into the surrounding structures. Schwannomas arise from the eighth cranial nerve. They are composed of spindle cells with mixed Antoni A and Antoni B cellular arrangements, verocay bodies,\u00a0and hyalinised vessels. [7] [8]", "contents": "Neurofibromatosis -- Histopathology. Neurofibromas are benign tumors with mixed cell types, including Schwann cells, perineural cells, and fibroblasts. The tumors also contain mast cells, axonal processes, and a collagenous extracellular matrix. Plexiform neurofibromas are similar to neurofibromas, but they arise from muscle nerve fascicles and can infiltrate into the surrounding structures. Schwannomas arise from the eighth cranial nerve. They are composed of spindle cells with mixed Antoni A and Antoni B cellular arrangements, verocay bodies,\u00a0and hyalinised vessels. [7] [8]"}
{"id": "article-25785_7", "title": "Neurofibromatosis -- History and Physical", "content": "Neurofibromatosis\u00a0type 1\u00a0has cutaneous and noncutaneous manifestations. Cafe-au-lait macules are one of the seven diagnostic criteria for neurofibromatosis\u00a0type 1. The lesions are sharply demarcated with a homogenous appearance. Axillary and groin freckling, or Crowe sign, is the most specific criteria for neurofibromatosis\u00a0type 1. Neurofibromas can occur anywhere on the body. They can be cutaneous or internal. Dermal tumors are soft dome-shaped tumors but can also present as pedunculated, nodular, or plaque-like. Internal tumors are deeper and can occur around the eye, retroperitoneal, along with the gastrointestinal (GI) tract, or in the mediastinum. Neurofibromas have the buttonhole sign. Plexiform neurofibromas are usually present from birth and are derived from the nerve sheaths. They can feel like a \"bag of worms.\" Cutaneous\u00a0manifestation includes scoliosis, long bone dysplasia, learning difficulties, and attention deficit hyperactivity disorder (ADHD). Lisch nodules are hyperpigmentation in the iris. They do not affect vision. Optic glioma is a tumor of the optic nerve and can affect vision. It occurs in 15% of patients with neurofibromatosis\u00a0type 1. Patients also have generalized hyperpigmentation, blue-red, pseudoatrophic macules, juvenile xanthogranuloma, glomus tumor, melanoma, nevus anemicus, and pruritus. Patients are at increased risk for rhabdomyosarcoma, myeloid leukemia, and pheochromocytomas.", "contents": "Neurofibromatosis -- History and Physical. Neurofibromatosis\u00a0type 1\u00a0has cutaneous and noncutaneous manifestations. Cafe-au-lait macules are one of the seven diagnostic criteria for neurofibromatosis\u00a0type 1. The lesions are sharply demarcated with a homogenous appearance. Axillary and groin freckling, or Crowe sign, is the most specific criteria for neurofibromatosis\u00a0type 1. Neurofibromas can occur anywhere on the body. They can be cutaneous or internal. Dermal tumors are soft dome-shaped tumors but can also present as pedunculated, nodular, or plaque-like. Internal tumors are deeper and can occur around the eye, retroperitoneal, along with the gastrointestinal (GI) tract, or in the mediastinum. Neurofibromas have the buttonhole sign. Plexiform neurofibromas are usually present from birth and are derived from the nerve sheaths. They can feel like a \"bag of worms.\" Cutaneous\u00a0manifestation includes scoliosis, long bone dysplasia, learning difficulties, and attention deficit hyperactivity disorder (ADHD). Lisch nodules are hyperpigmentation in the iris. They do not affect vision. Optic glioma is a tumor of the optic nerve and can affect vision. It occurs in 15% of patients with neurofibromatosis\u00a0type 1. Patients also have generalized hyperpigmentation, blue-red, pseudoatrophic macules, juvenile xanthogranuloma, glomus tumor, melanoma, nevus anemicus, and pruritus. Patients are at increased risk for rhabdomyosarcoma, myeloid leukemia, and pheochromocytomas."}
{"id": "article-25785_8", "title": "Neurofibromatosis -- History and Physical", "content": "Neurofibromatosis\u00a0type 2\u00a0patients present most commonly with schwannomas and meningiomas. Bilateral\u00a0vestibular\u00a0schwannoma\u00a0and unilateral\u00a0vestibular\u00a0schwannoma\u00a0occur on the superior division of the eighth cranial nerve. This is the most common type, but it can occur with any cranial nerve. Involvement of the facial nerve with the\u00a0vestibular\u00a0schwannoma\u00a0can make surgical treatment difficult. These patients present with tinnitus, hearing loss, and difficulty with balance. Patients that have the truncated protein were found to have the disease of onset at a younger age and a higher prevalence of tumors. Younger patients also have an earlier onset of symptoms. [9]", "contents": "Neurofibromatosis -- History and Physical. Neurofibromatosis\u00a0type 2\u00a0patients present most commonly with schwannomas and meningiomas. Bilateral\u00a0vestibular\u00a0schwannoma\u00a0and unilateral\u00a0vestibular\u00a0schwannoma\u00a0occur on the superior division of the eighth cranial nerve. This is the most common type, but it can occur with any cranial nerve. Involvement of the facial nerve with the\u00a0vestibular\u00a0schwannoma\u00a0can make surgical treatment difficult. These patients present with tinnitus, hearing loss, and difficulty with balance. Patients that have the truncated protein were found to have the disease of onset at a younger age and a higher prevalence of tumors. Younger patients also have an earlier onset of symptoms. [9]"}
{"id": "article-25785_9", "title": "Neurofibromatosis -- Evaluation", "content": "NIH has seven diagnostic criteria for neurofibromatosis\u00a0type 1. Two must be met for the diagnosis of\u00a0neurofibromatosis\u00a0type 1. Genetic testing is not routinely done. Six\u00a0or more cafe-au-lait spots greater than 5 mm prepubertal and greater than 15 mm post-pubertal Two\u00a0or more neurofibromas or one or more plexiform neurofibroma Axillary or groin freckling Optic glioma Two or more Lisch nodules Sphenoid dysplasia, dysplasia or thinning of long bone cortex First-degree relative with\u00a0neurofibromatosis\u00a0type 1", "contents": "Neurofibromatosis -- Evaluation. NIH has seven diagnostic criteria for neurofibromatosis\u00a0type 1. Two must be met for the diagnosis of\u00a0neurofibromatosis\u00a0type 1. Genetic testing is not routinely done. Six\u00a0or more cafe-au-lait spots greater than 5 mm prepubertal and greater than 15 mm post-pubertal Two\u00a0or more neurofibromas or one or more plexiform neurofibroma Axillary or groin freckling Optic glioma Two or more Lisch nodules Sphenoid dysplasia, dysplasia or thinning of long bone cortex First-degree relative with\u00a0neurofibromatosis\u00a0type 1"}
{"id": "article-25785_10", "title": "Neurofibromatosis -- Evaluation", "content": "Differential diagnosis includes\u00a0neurofibromatosis\u00a0type 1-like syndrome, familial cafe-au-lait spots, and segmental\u00a0neurofibromatosis\u00a0type 1. The nf1-like syndrome was first described in 2007. Patients with the\u00a0neurofibromatosis\u00a0type 1-like syndrome have cafe-au-lait spots, axillary freckling, and macrocephaly, but they lack the NF1 genetic mutation, neurofibromas, and Lisch nodules. It is an autosomal dominant disease due to a mutation in the SPRED1 gene on chromosome 15.\u00a0Familial cafe-au-lait spots is a disorder presenting with only cafe-au-lait macules.", "contents": "Neurofibromatosis -- Evaluation. Differential diagnosis includes\u00a0neurofibromatosis\u00a0type 1-like syndrome, familial cafe-au-lait spots, and segmental\u00a0neurofibromatosis\u00a0type 1. The nf1-like syndrome was first described in 2007. Patients with the\u00a0neurofibromatosis\u00a0type 1-like syndrome have cafe-au-lait spots, axillary freckling, and macrocephaly, but they lack the NF1 genetic mutation, neurofibromas, and Lisch nodules. It is an autosomal dominant disease due to a mutation in the SPRED1 gene on chromosome 15.\u00a0Familial cafe-au-lait spots is a disorder presenting with only cafe-au-lait macules."}
{"id": "article-25785_11", "title": "Neurofibromatosis -- Evaluation", "content": "Bilateral vestibular\u00a0schwannoma is pathognomic for\u00a0neurofibromatosis\u00a0type 2, but not all patients with neurofibromatosis\u00a0type 2\u00a0have bilateral\u00a0vestibular\u00a0schwannoma. The NIH has diagnostic criteria for neurofibromatosis\u00a0type 2. Definitive Neurofibromatosis Type 2 Bilateral\u00a0vestibular\u00a0schwannoma\u00a0or a first-degree relative with\u00a0neurofibromatosis\u00a0type 2\u00a0plus unilateral\u00a0vestibular\u00a0schwannoma\u00a0in someone less than 30 or any two of the following: meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacities/juvenile cortical cataract Presumptive or Probable Neurofibromatosis Type 2", "contents": "Neurofibromatosis -- Evaluation. Bilateral vestibular\u00a0schwannoma is pathognomic for\u00a0neurofibromatosis\u00a0type 2, but not all patients with neurofibromatosis\u00a0type 2\u00a0have bilateral\u00a0vestibular\u00a0schwannoma. The NIH has diagnostic criteria for neurofibromatosis\u00a0type 2. Definitive Neurofibromatosis Type 2 Bilateral\u00a0vestibular\u00a0schwannoma\u00a0or a first-degree relative with\u00a0neurofibromatosis\u00a0type 2\u00a0plus unilateral\u00a0vestibular\u00a0schwannoma\u00a0in someone less than 30 or any two of the following: meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacities/juvenile cortical cataract Presumptive or Probable Neurofibromatosis Type 2"}
{"id": "article-25785_12", "title": "Neurofibromatosis -- Evaluation", "content": "Unilateral\u00a0vestibular\u00a0schwannoma\u00a0in someone under 30 plus one of the following: meningioma,\u00a0schwannoma,\u00a0glioma, juvenile posterior subcapsular lenticular opacities/juvenile cortical cataract Multiple meningiomas (2 or greater) plus unilateral\u00a0vestibular\u00a0schwannoma\u00a0less than 30 years or one of the following: schwannoma glioma, juvenile posterior subcapsular lenticular opacities/juvenile cortical cataract [10]", "contents": "Neurofibromatosis -- Evaluation. Unilateral\u00a0vestibular\u00a0schwannoma\u00a0in someone under 30 plus one of the following: meningioma,\u00a0schwannoma,\u00a0glioma, juvenile posterior subcapsular lenticular opacities/juvenile cortical cataract Multiple meningiomas (2 or greater) plus unilateral\u00a0vestibular\u00a0schwannoma\u00a0less than 30 years or one of the following: schwannoma glioma, juvenile posterior subcapsular lenticular opacities/juvenile cortical cataract [10]"}
{"id": "article-25785_13", "title": "Neurofibromatosis -- Treatment / Management", "content": "Cafe-au-lait spots and neurofibromas are benign and do not require treatment. Surgical excision can be performed on symptomatic lesions, but the recurrence can occur. Plexiform neurofibromas have malignant potential. There is an 8% to 13% risk for plexiform neurofibromas to develop into malignant peripheral nerve sheath tumors. This should be suspected if there is pain for more than\u00a0one month, new neurologic deficits, change of the neurofibroma from soft to hard, or a rapid increase in size. These malignancies are treated with wide local excision. Imatinib has been shown to decrease plexiform neurofibroma size.", "contents": "Neurofibromatosis -- Treatment / Management. Cafe-au-lait spots and neurofibromas are benign and do not require treatment. Surgical excision can be performed on symptomatic lesions, but the recurrence can occur. Plexiform neurofibromas have malignant potential. There is an 8% to 13% risk for plexiform neurofibromas to develop into malignant peripheral nerve sheath tumors. This should be suspected if there is pain for more than\u00a0one month, new neurologic deficits, change of the neurofibroma from soft to hard, or a rapid increase in size. These malignancies are treated with wide local excision. Imatinib has been shown to decrease plexiform neurofibroma size."}
{"id": "article-25785_14", "title": "Neurofibromatosis -- Treatment / Management", "content": "Monitoring for any neurologic changes and referral to a neurologist is paramount. These changes can be due to tumor development. Consistent ophthalmologic evaluation is recommended for observation of the development of optic gliomas. Chemotherapy is the treatment of choice for optic gliomas.", "contents": "Neurofibromatosis -- Treatment / Management. Monitoring for any neurologic changes and referral to a neurologist is paramount. These changes can be due to tumor development. Consistent ophthalmologic evaluation is recommended for observation of the development of optic gliomas. Chemotherapy is the treatment of choice for optic gliomas."}
{"id": "article-25785_15", "title": "Neurofibromatosis -- Treatment / Management", "content": "Monitoring children for difficulty learning and behavioral issues is important. Counseling can be beneficial for patients to provide support regarding the disease's autosomal dominant inheritance pattern. Neurofibromatosis type 2", "contents": "Neurofibromatosis -- Treatment / Management. Monitoring children for difficulty learning and behavioral issues is important. Counseling can be beneficial for patients to provide support regarding the disease's autosomal dominant inheritance pattern. Neurofibromatosis type 2"}
{"id": "article-25785_16", "title": "Neurofibromatosis -- Treatment / Management", "content": "Patients with neurofibromatosis\u00a0type 2 require the assessment of their hearing. Ophthalmology evaluation, MRI, audiology, and brainstem evoked potentials are important in managing these patients. Surgery is still the first-line treatment for symptomatic tumors, but there is a 44% recurrence rate. Radiation can be used, but there is an increased risk of malignant transformation. Bevacizumab,\u00a0a VEGF inhibitor, is a monoclonal antibody and can be used to treat neurofibromatosis type 2 patients medically. It decreased tumor size in 53% of cases and improved hearing in 57%. Patients with suspected\u00a0neurofibromatosis\u00a0type 2\u00a0should have an MRI of the head and spine done. Getting thin cuts through the internal auditory canals is important. Treatment is done if the tumor is compressing the brainstem or preventing hearing loss. [11] [12] [13]", "contents": "Neurofibromatosis -- Treatment / Management. Patients with neurofibromatosis\u00a0type 2 require the assessment of their hearing. Ophthalmology evaluation, MRI, audiology, and brainstem evoked potentials are important in managing these patients. Surgery is still the first-line treatment for symptomatic tumors, but there is a 44% recurrence rate. Radiation can be used, but there is an increased risk of malignant transformation. Bevacizumab,\u00a0a VEGF inhibitor, is a monoclonal antibody and can be used to treat neurofibromatosis type 2 patients medically. It decreased tumor size in 53% of cases and improved hearing in 57%. Patients with suspected\u00a0neurofibromatosis\u00a0type 2\u00a0should have an MRI of the head and spine done. Getting thin cuts through the internal auditory canals is important. Treatment is done if the tumor is compressing the brainstem or preventing hearing loss. [11] [12] [13]"}
{"id": "article-25785_17", "title": "Neurofibromatosis -- Differential Diagnosis", "content": "Acoustic neuroma Brainstem syndromes Caf\u00e9-au-lait spots Legius syndrome (SPRED1 -related caf\u00e9-au-lait spots and freckles) McCune-Albright syndrome Spinal injury", "contents": "Neurofibromatosis -- Differential Diagnosis. Acoustic neuroma Brainstem syndromes Caf\u00e9-au-lait spots Legius syndrome (SPRED1 -related caf\u00e9-au-lait spots and freckles) McCune-Albright syndrome Spinal injury"}
{"id": "article-25785_18", "title": "Neurofibromatosis -- Enhancing Healthcare Team Outcomes", "content": "The management of neurofibromatosis is best done with an interprofessional team, including dermatologists, neurologists, pediatricians, and genetic counselors. The key is to monitor the patient for CNS tumors, which, if detected late, have a poor prognosis. Genetic counseling should be available to patients with an affected child. The dermatologist, ophthalmologist, neurosurgeon, neurologist, and general surgeon should regularly follow up with these patients to ensure that no mass lesions are developing in the body.", "contents": "Neurofibromatosis -- Enhancing Healthcare Team Outcomes. The management of neurofibromatosis is best done with an interprofessional team, including dermatologists, neurologists, pediatricians, and genetic counselors. The key is to monitor the patient for CNS tumors, which, if detected late, have a poor prognosis. Genetic counseling should be available to patients with an affected child. The dermatologist, ophthalmologist, neurosurgeon, neurologist, and general surgeon should regularly follow up with these patients to ensure that no mass lesions are developing in the body."}
{"id": "article-25785_19", "title": "Neurofibromatosis -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Neurofibromatosis -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}